Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33525545 | 0.87 | HPGD (0.43) | SMN1; SMN2OPRK1HSD17B10CHRM2CHRM1 | |
| SCHEMBL33525876 | 0.87 | HSD17B10 (0.41) | SMN1; SMN2OPRK1HSD17B10CHRM2CHRM1 | |
| SCHEMBL31085807 | 0.84 | HSD17B10 (0.36) | USP2SMN1; SMN2RECQLOPRK1HSD17B10 | |
| SCHEMBL31208605 | 0.84 | HSD17B10 (0.36) | USP2SMN1; SMN2RECQLOPRK1HSD17B10 | |
| SCHEMBL31085624 | 0.84 | HSD17B10 (0.36) | USP2SMN1; SMN2RECQLOPRK1HSD17B10 | |
| SCHEMBL31085636 | 0.84 | HSD17B10 (0.36) | USP2SMN1; SMN2RECQLOPRK1HSD17B10 | |
| SCHEMBL31209211 | 0.81 | PIK3CD (0.37) | SMN1; SMN2OPRK1HSD17B10CHRM2CHRM1 | |
| SCHEMBL31209419 | 0.81 | HRH3 (0.45) | OPRK1HSD17B10CHRM2CHRM1CHRM3 | |
| SCHEMBL33525498 | 0.79 | HSD17B10 (0.38) | SMN1; SMN2OPRK1HSD17B10CHRM2CHRM1 | |
| SCHEMBL33527004 | 0.79 | HSD17B10 (0.38) | SMN1; SMN2OPRK1HSD17B10CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | USP2 3256/4885SMN1; SMN2 4044/4885RECQL 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.